Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Neuroone Medical Technologies (NMTC) Accumulated Depreciation & Amortization (2020 - 2026)

Neuroone Medical Technologies filings provide 7 years of Accumulated Depreciation & Amortization readings, the most recent being $913218.0 for Q1 2026.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 34.48% to $913218.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $913218.0, a 34.48% increase, with the full-year FY2025 number at $798823.0, up 42.78% from a year prior.
  • Accumulated Depreciation & Amortization hit $913218.0 in Q1 2026 for Neuroone Medical Technologies, up from $858768.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $540.0 billion in Q3 2022 to a low of $132586.0 in Q1 2022.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $500912.0 (2024), compared with a mean of $31.8 billion.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 599604180.19% in 2022 and later plummeted 100.0% in 2023.
  • Neuroone Medical Technologies' Accumulated Depreciation & Amortization stood at $216667.0 in 2022, then skyrocketed by 79.11% to $388062.0 in 2023, then skyrocketed by 59.51% to $619008.0 in 2024, then skyrocketed by 38.73% to $858768.0 in 2025, then increased by 6.34% to $913218.0 in 2026.
  • The last three reported values for Accumulated Depreciation & Amortization were $913218.0 (Q1 2026), $858768.0 (Q4 2025), and $798823.0 (Q3 2025) per Business Quant data.